Are you looking to further reduce debt? What is your strategy? Debt reduction is a priority for Biocon Group and Biocon Biologics. Last fiscal, we reduced $250 million in acquisition debt.

Biocon’s subsidiary, Biocon Biologics Limited (BBL), has announced the completion of its first year as a fully integrated ...

Biocon shares rose 9% to ₹389, driven by positive developments including Japanese approval for its biosimilar Ustekinumab. Jefferies upgraded its rating to 'Hold' with a target of ₹400, citing ...

Biocon Pharma, a subsidiary of Biocon, got China’s approval for Tacrolimus capsules (0.5mg, 1mg, 5mg). The immunosuppressant helps prevent organ rejection in transplant patients and strengthens ...

On December 10, the markets saw a block trade involving ₹706 Crore in shares of Contract Development Manufacturing Organisation (CDMO) participant Syngene International, with promoter Biocon ...

For Biocon to a certain extent ... on the EBITDA front is something to be watched out for. Obviously, the net debt has ...